TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment

TS-066100 — Research tool to transfect cells ex vivo using electroporation through electrospun core-shell fibers for research applications

TS-063433 — A new pharmacologic modality for treating AFib.

TS-062822 — Dual payload ADC chemo-immunotherapy and Humanized mAb for cancer treatment

TS-062540 — General methods for purifying proteins that can be used in various applications such as targeted drug delivery, bioimaging, and hemolysis treatment.

TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.

TS-041485 — A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.